TN8.DE
Thermo Fisher Scientific Inc.
TN8.DE
(0.2)551,00 EUR
15.9% ROA
14.23% ROE
36.8x PER
228.959.813.601,94 EUR
74.64% DER
0.25% Yield
15.55% NPM
Thermo Fisher Scientific Inc. Stock Analysis
Thermo Fisher Scientific Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
Dividend
The company's track record of consistently paying dividends in the last three years highlights its dedication to providing investors with regular income. |
|
| 2 |
ROE
Unidentified ROE |
|
| 3 |
ROA
Unidentified ROA |
|
| 4 |
PBV
Unidentified ROA |
|
| 5 |
DER
Unidentified DER |
|
| 6 |
Revenue Growth
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity. |
|
| 7 |
Net Profit Growth
The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity. |
|
| 8 |
Assets Growth
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice. |
|
| 9 |
Graham Number
Unidentified Graham Number |
|
| 10 |
Dividend Growth
Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns. |
|
| 11 |
Buffet Intrinsic Value
The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value. |
Thermo Fisher Scientific Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Hold |
| 2 | MACD | Buy |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Sell |
Thermo Fisher Scientific Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2016 | 17.325.528.017 | |
| 2017 | 17.420.050.204 | 0.54% |
| 2018 | 21.307.793.808 | 18.25% |
| 2019 | 22.754.575.998 | 6.36% |
| 2020 | 26.331.578.092 | 13.58% |
| 2021 | 34.497.290.259 | 23.67% |
| 2022 | 41.966.830.179 | 17.8% |
| 2023 | 38.828.890.861 | -8.08% |
| 2024 | 42.164.000.000 | 7.91% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2016 | 715.619.841 | |
| 2017 | 739.506.864 | 3.23% |
| 2018 | 845.908.392 | 12.58% |
| 2019 | 893.541.607 | 5.33% |
| 2020 | 965.224.214 | 7.43% |
| 2021 | 1.236.979.166 | 21.97% |
| 2022 | 1.374.445.223 | 10% |
| 2023 | 1.211.336.003 | -13.47% |
| 2024 | 1.356.000.000 | 10.67% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2016 | 0 | |
| 2017 | 0 | 0% |
| 2018 | 0 | 0% |
| 2019 | 0 | 0% |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
| 2024 | 0 | 0% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2016 | 4.377.245.954 | |
| 2017 | 4.413.723.400 | 0.83% |
| 2018 | 5.369.375.088 | 17.8% |
| 2019 | 5.822.719.784 | 7.79% |
| 2020 | 8.354.379.268 | 30.3% |
| 2021 | 11.358.037.725 | 26.45% |
| 2022 | 11.124.503.620 | -2.1% |
| 2023 | 9.832.025.658 | -13.15% |
| 2024 | 11.948.000.000 | 17.71% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2016 | 8.136.430.735 | |
| 2017 | 8.060.458.262 | -0.94% |
| 2018 | 9.612.038.688 | 16.14% |
| 2019 | 10.106.017.936 | 4.89% |
| 2020 | 13.098.770.938 | 22.85% |
| 2021 | 17.273.719.032 | 24.17% |
| 2022 | 17.763.139.453 | 2.76% |
| 2023 | 15.577.944.081 | -14.03% |
| 2024 | 17.388.000.000 | 10.41% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2016 | 1.916.852.405 | |
| 2017 | 1.852.931.050 | -3.45% |
| 2018 | 2.570.091.888 | 27.9% |
| 2019 | 3.292.651.824 | 21.94% |
| 2020 | 6.375.000.000 | 48.35% |
| 2021 | 7.725.000.000 | 17.48% |
| 2022 | 6.950.000.000 | -11.15% |
| 2023 | 5.995.000.000 | -15.93% |
| 2024 | 6.192.000.000 | 3.18% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2016 | 5 | |
| 2017 | 5 | 0% |
| 2018 | 6 | 33.33% |
| 2019 | 8 | 25% |
| 2020 | 13 | 38.46% |
| 2021 | 17 | 23.53% |
| 2022 | 17 | -6.25% |
| 2023 | 14 | -14.29% |
| 2024 | 15 | 6.67% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2016 | 2.571.130.695 | |
| 2017 | 2.912.224.666 | 11.71% |
| 2018 | 3.311.027.160 | 12.04% |
| 2019 | 3.605.346.843 | 8.16% |
| 2020 | 5.569.858.610 | 35.27% |
| 2021 | 5.972.867.399 | 6.75% |
| 2022 | 6.457.369.774 | 7.5% |
| 2023 | 6.275.934.550 | -2.89% |
| 2024 | 1.659.000.000 | -278.3% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2016 | 2.992.462.779 | |
| 2017 | 3.335.275.890 | 10.28% |
| 2018 | 3.974.107.368 | 16.07% |
| 2019 | 4.430.291.537 | 10.3% |
| 2020 | 6.774.549.966 | 34.6% |
| 2021 | 8.192.567.567 | 17.31% |
| 2022 | 8.553.141.789 | 4.22% |
| 2023 | 7.615.924.040 | -12.31% |
| 2024 | 1.960.000.000 | -288.57% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2016 | 421.332.084 | |
| 2017 | 423.051.224 | 0.41% |
| 2018 | 663.080.208 | 36.2% |
| 2019 | 824.944.694 | 19.62% |
| 2020 | 1.204.691.356 | 31.52% |
| 2021 | 2.219.700.168 | 45.73% |
| 2022 | 2.095.772.015 | -5.91% |
| 2023 | 1.339.989.490 | -56.4% |
| 2024 | 301.000.000 | -345.18% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2016 | 20.421.238.015 | |
| 2017 | 21.163.387.314 | 3.51% |
| 2018 | 24.131.570.736 | 12.3% |
| 2019 | 26.436.537.575 | 8.72% |
| 2020 | 28.210.536.998 | 6.29% |
| 2021 | 36.050.992.398 | 21.75% |
| 2022 | 41.250.175.192 | 12.6% |
| 2023 | 42.439.342.598 | 2.8% |
| 2024 | 47.535.000.000 | 10.72% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2016 | 43.524.533.490 | |
| 2017 | 47.192.696.482 | 7.77% |
| 2018 | 49.190.404.032 | 4.06% |
| 2019 | 52.009.823.089 | 5.42% |
| 2020 | 56.435.785.288 | 7.84% |
| 2021 | 83.687.887.105 | 32.56% |
| 2022 | 90.776.921.280 | 7.81% |
| 2023 | 89.446.790.004 | -1.49% |
| 2024 | 98.496.000.000 | 9.19% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2016 | 23.103.295.474 | |
| 2017 | 26.029.309.168 | 11.24% |
| 2018 | 25.058.833.296 | -3.87% |
| 2019 | 25.573.285.514 | 2.01% |
| 2020 | 28.225.248.290 | 9.4% |
| 2021 | 47.636.894.707 | 40.75% |
| 2022 | 49.526.746.087 | 3.82% |
| 2023 | 47.007.447.406 | -5.36% |
| 2024 | 50.961.000.000 | 7.76% |
Thermo Fisher Scientific Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 104.7
- Net Income per Share
- 16.29
- Price to Earning Ratio
- 36.8x
- Price To Sales Ratio
- 5.72x
- POCF Ratio
- 26.09
- PFCF Ratio
- 30.64
- Price to Book Ratio
- 4.83
- EV to Sales
- 6.43
- EV Over EBITDA
- 24.28
- EV to Operating CashFlow
- 29.32
- EV to FreeCashFlow
- 34.43
- Earnings Yield
- 0.03
- FreeCashFlow Yield
- 0.03
- Market Cap
- 228,96 Bil.
- Enterprise Value
- 257,29 Bil.
- Graham Number
- 213.3
- Graham NetNet
- -84.99
Income Statement Metrics
- Net Income per Share
- 16.29
- Income Quality
- 1.49
- ROE
- 0.14
- Return On Assets
- 0.06
- Return On Capital Employed
- 0.08
- Net Income per EBT
- 0.96
- EBT Per Ebit
- 0.91
- Ebit per Revenue
- 0.18
- Effective Tax Rate
- 0.09
Margins
- Sales, General, & Administrative to Revenue
- 0
- Research & Developement to Revenue
- 0.03
- Stock Based Compensation to Revenue
- 0.01
- Gross Profit Margin
- 0.4
- Operating Profit Margin
- 0.18
- Pretax Profit Margin
- 0.16
- Net Profit Margin
- 0.16
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0.25
- Payout Ratio
- 0.08
- Dividend Per Share
- 1.52
Operating Metrics
- Operating Cashflow per Share
- 22.97
- Free CashFlow per Share
- 19.56
- Capex to Operating CashFlow
- 0.15
- Capex to Revenue
- 0.03
- Capex to Depreciation
- 0.42
- Return on Invested Capital
- 0.08
- Return on Tangible Assets
- 0.16
- Days Sales Outstanding
- 86.06
- Days Payables Outstanding
- 38.64
- Days of Inventory on Hand
- 78.86
- Receivables Turnover
- 4.24
- Payables Turnover
- 9.45
- Inventory Turnover
- 4.63
- Capex per Share
- 3.41
Balance Sheet
- Cash per Share
- 23,10
- Book Value per Share
- 124,44
- Tangible Book Value per Share
- -30.96
- Shareholders Equity per Share
- 124.17
- Interest Debt per Share
- 96.52
- Debt to Equity
- 0.75
- Debt to Assets
- 0.36
- Net Debt to EBITDA
- 2.67
- Current Ratio
- 1.72
- Tangible Asset Value
- -11,83 Bil.
- Net Current Asset Value
- -25,49 Bil.
- Invested Capital
- 79348000000
- Working Capital
- 10,70 Bil.
- Intangibles to Total Assets
- 0.6
- Average Receivables
- 9,05 Bil.
- Average Payables
- 2,46 Bil.
- Average Inventory
- 4977591288
- Debt to Market Cap
- 0.15
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|---|---|
| 2012 | 1 | |
| 2013 | 0 | 0% |
| 2021 | 1 | 100% |
| 2022 | 1 | 0% |
| 2023 | 1 | 0% |
| 2024 | 1 | 0% |
Thermo Fisher Scientific Inc. Profile
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
- CEO
- Mr. Marc N. Casper
- Employee
- 122.000
- Address
-
168 Third Avenue
Waltham, 02451
Thermo Fisher Scientific Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Mr. Michael A. Boxer Esq. Senior Vice President & General Counsel |
70 |
| 2 |
Mr. Rafael Tejada Vice President of Investor Relations |
70 |
| 3 |
Mr. Marc N. Casper Chairman, President & Chief Executive Officer |
70 |
| 4 |
Mr. Ryan J. Snyder Senior Vice President & Chief Information Officer |
70 |
| 5 |
Mr. Stephen Williamson Senior Vice President & Chief Financial Officer |
70 |
| 6 |
Mr. Michel Lagarde Executive Vice President & Chief Operating Officer |
70 |
| 7 |
Ms. Lisa P. Britt Chief Human Resources Officer & Senior Vice President |
70 |
| 8 |
Mr. Gianluca Pettiti Executive Vice President |
70 |
| 9 |
Mr. Joseph R. Holmes Vice President & Chief Accounting Officer |
70 |
| 10 |
Dr. Karen E. Nelson Ph.D. Chief Scientific Officer |
70 |